CovidResearchTrials by Shray Alag

CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)

SAB-185Wiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (8)

Name (Synonyms) Correlation
drug508 Calcium Channel Blockers Wiki 0.71
drug176 Angiotensin receptor blocker Wiki 0.71
drug2507 Thiazide or Thiazide-like diuretics Wiki 0.71
drug1642 Normal Saline Wiki 0.50
drug53 ACE inhibitor Wiki 0.41
drug215 Ascorbic Acid Wiki 0.35
drug1645 Normal saline Wiki 0.32
drug1103 Hydroxychloroquine Sulfate Wiki 0.20

Correlated MeSH Terms (5)

Name (Synonyms) Correlation
D006973 Hypertension NIH 0.20
D013577 Syndrome NIH 0.08
D018352 Coronavirus Infections NIH 0.06
D007239 Infection NIH 0.04
D045169 Severe Acute Respiratory Syndrome NIH 0.04

Correlated HPO Terms (1)

Name (Synonyms) Correlation
HP:0000822 Hypertension HPO 0.20

There are 2 clinical trials

Clinical Trials

1 A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single and Multiple Ascending Dose Study of SAB-185 in Healthy Subjects

Coronavirus disease 2019 (COVID-19) is an infectious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). SAB Biotherapeutics has developed SAB-185, an Anti-SARS-CoV-2 Human Immunoglobulin Intravenous (transchromosomic [Tc] bovine-derived), as a potential therapeutic to treat COVID-19. This study will evaluate the safety, immunogenicity, and pharmacokinetics of SAB-185 in healthy participants.

NCT04468958 COVID-19 SARS-CoV2 Biological: SAB-185 Other: Normal saline

Primary Outcomes

Description: Incidence and severity of other adverse events and severe adverse events (SAE)

Measure: Number of Participants Having Adverse Events

Time: 29 Days

Description: transfusion-related adverse events

Measure: Number of Participants Having Transfusion-Related Adverse Events

Time: 29 Days

Secondary Outcomes

Description: Incidence and severity of adverse events and SAEs from Screening through Study Day 90

Measure: Number of Participants Having Adverse Events

Time: 90 Days

Description: SARS-CoV-2 binding (ELISA) and neutralizing (PRNT80) antibody titers from Screening through Study Day 90

Measure: Pharmacokinetics from screening to day 90

Time: 90 Days

2 A Phase 1B, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study of SAB-185 in Ambulatory Subjects With COVID-19

: Coronavirus disease 2019 (COVID-19) is an infectious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). SAB Biotherapeutics has developed SAB-185, an Anti-SARS-CoV-2 Human Immunoglobulin Intravenous (transchromosomic [Tc] bovine-derived), as a potential therapeutic to treat COVID-19. This study will evaluate the safety, immunogenicity, and pharmacokinetics of SAB-185 in ambulatory participants with COVID-19.

NCT04469179 COVID-19 SARS-CoV2 Biological: SAB-185 Other: Normal Saline

Primary Outcomes

Description: Incidence and severity of other adverse events and severe adverse events (SAE)

Measure: Number of Participants Having Adverse Events

Time: 29 Days

Description: transfusion-related adverse events

Measure: Number of Participants Having Transfusion-Related Adverse Events

Time: 29 Days

Secondary Outcomes

Description: Incidence and severity of adverse events and SAEs from Screening through Study Day 90

Measure: Number of Participants Having Adverse Events

Time: 90 Days

Description: Measurement of SARS CoV-2 neutralizing (PRNT80) antibody titers from screening through Study Day 90

Measure: Assesment of the PD of SAB-185 administered intravenously

Time: 90 Days

Description: Measurement of Rheumatoid factor through day 90

Measure: Immune response elicited by SAB-185

Time: 90 Days

Description: Measurement of anti-SAB-185 antibodies through screening day 90

Measure: Concentration of subject anti-SAB-185 antibodies elicited by SAB-185

Time: 90 Days

Description: Incidence of SARS-CoV-2 in swab specimens as measured by quantitative RT-PCR through Study Day 29

Measure: Incidence of SARS-CoV-2 in oropharyngeal (OP) or nasopharyngeal (NP) swab specimens

Time: 29 Days

Description: Level of SARS-CoV-2 in swab specimens as measured by quantitative RT-PCR through Study Day 29

Measure: Level of SARS-CoV-2 in oropharyngeal (OP) or nasopharyngeal (NP) swab specimens

Time: 29 Days

No related HPO nodes (Using clinical trials)